Efficacy of tezepelumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis
European Archives of Oto-Rhino-Laryngology · 2026-08 · 283 (8) · 4875-4884
DOI: 10.1007/s00405-026-10286-w ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Archives of Oto-Rhino-Laryngology, online erschienen am 21.05.2026. Verfasst von Do Hyun Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. Hauptthemen laut MEDLINE: Nasal Polyps, Rhinosinusitis. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To evaluate the efficacy of tezepelumab as an adjunctive treatment in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). METHODS: PubMed, SCOPUS, Embase, Web of Science, and the Cochrane Library were systematically searched from database inception through January 2026. Eligible studies compared tezepelumab with placebo or reported pre-post treatment outcomes in tezepelumab-treated cohorts. Outcomes included nasal and olfactory symptom measures (nasal congestion, nasal polyp score, olfactory testing, olfactory-related symptoms, and the Sino-Nasal Outcome Test-22 [SNOT-22]), asthma-related measures (pre-bronchodilator forced expiratory volume in 1 s [FEV1] and the Asthma Control Questionnaire [ACQ]-6), and treatment-related adverse events. RESULTS: Four studies involving 702 participants met the inclusion criteria. Pre-post analyses demonstrated significant improvements following tezepelumab treatment in nasal congestion (mean difference [MD] 1.6859, 95% confidence interval [CI] [1.3882; 1.9836]), olfactory function (standardized mean difference [SMD] - 1.17, 95% CI - 1.39 to - 0.95), SNOT-22 scores (MD 28.6091, 95% CI [15.9241; 41.2940]), and asthma control (ACQ SMD 1.06, 95% CI 0.54-1.57). Both the asthma with nasal polyps and CRSwNP subgroups exhibited consistent symptom improvement. Changes in FEV1 were modest and did not reach statistical significance. CONCLUSION: Tezepelumab was associated with significant improvements in rhinologic and asthma-related outcomes in patients with CRSwNP. Larger, well-designed randomized controlled trials are warranted to confirm these findings and to define more accurately the long-term therapeutic role of tezepelumab in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine, Durham, NC, USA.
- Department of Otolaryngology-Head and Neck Surgery, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. yellobird@catholic.ac.kr.
Zitieren
APA
Kim, D. H., Jang, D. W., & Hwang, S. H. (2026). Efficacy of tezepelumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis. European Archives of Oto-Rhino-Laryngology, 283(8), 4875-4884. https://doi.org/10.1007/s00405-026-10286-w
Vancouver
Kim DH, Jang DW, Hwang SH. Efficacy of tezepelumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis. European Archives of Oto-Rhino-Laryngology. 2026;283(8):4875-4884. doi:10.1007/s00405-026-10286-w
BibTeX
@article{Kim2026,
author = {Kim, Do Hyun and Jang, David W and Hwang, Se Hwan},
title = {Efficacy of tezepelumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis},
journal = {European Archives of Oto-Rhino-Laryngology},
year = {2026},
volume = {283},
number = {8},
pages = {4875--4884},
doi = {10.1007/s00405-026-10286-w}
}
EUVIMED